Mouse plasmacytoma: An experimental model of human multiple myeloma

Haematologica

Volumn 86, Issue 3, 2001, Pages 227-236

  Gado K ^a   Silva, S ^a   Paloczi K ^a   Domjan G ^a   Falus, A ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Animal model; Experimental plasmacytoma; Multiple myeloma; Transgenic mice; Tumorigenesis

Indexed keywords

INTERLEUKIN 6; PHOSPHONIC ACID DERIVATIVE; PRISTANE; PROSTAGLANDIN; SOMATOMEDIN C;

ANIMAL MODEL; CELL TRANSFORMATION; CYTOGENETICS; DISEASE MODEL; GENE TRANSFER; IMMUNE SYSTEM; IMMUNOGLOBULIN GENE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE C MYC; OSTEOLYSIS; PATHOGENESIS; PLASMACYTOMA; REVIEW; SCID MOUSE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; CARCINOGENS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MULTIPLE MYELOMA; PLASMACYTOMA; TERPENES;

EID: 0035072851     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Multiple myeloma: Increasing evidence for a multistep transformation process
2. Immunoregulatory mechanisms in multiple myeloma
3. Interleukin-6 in human multiple myeloma
4. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
5. Selective expression of one c-myc allele in two human myeloma cell lines
6. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations
7. Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas
8. Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis
9. Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations
10. Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C alpha gene from chromosome 12 in two murine plasmacytomas
11. Experimental plasmacytomagenesis in mice
12. Murine plasmacytomas, carrier of the t(12;15) chromosomal translocation, develop from immature/mature B cells not from differentiated plasma cells
13. Plasmacytoma induction in specific pathogen-free (SPF) bcl-2 transgenic BALB/c mice
14. Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice
15. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice
16. Generation of plasmacytomas with the chromosomal translocation t(12;15) in the interleukin 6 transgenic mice
17. Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells
18. E-series prostaglandins are potent growth inhibitors for some B lymphomas
19. Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins
20. Inhibition of plasmacytoma development in BALB/c mice by indomethacin
21. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain
22. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5
23. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma
24. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth
25. Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines
26. Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas
27. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
28. Constitutive acti'vation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas
29. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth
30. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth
31. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells
32. Genetics of susceptibility to plasmacytoma development in BALB/c mice
33. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: Reduced susceptibility in a BALB/cJ with a brief description of pristane-induced arthritis
34. DNA repair in the c-myc proto-oncogene locus: Possible involvement in susceptibility or resistance to plasmacytoma induction in BALB/c mice
35. The plasmacytoma resistance gene, Pctr2, delays the onset of tumorigenesis and resides in the telomeric region of chromosome 4
36. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis
37. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane
38. Studies on the pathogenesis of plasma cell tumors. II. The role of mast cells and pituitary glycoprotein hormones in the inhibition of plasma cell tumorigenesis
39. The requirement of an adherent substratum for the growth of developing plasmacytoma cells in vivo
40. Disseminated growth of murine plasmacytoma: Similarities to multiple myeloma
41. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma
42. Animal model of human disease. Multiple myeloma
43. In vivo models for studying the role of autocrine or paracrine growth factors in hematologic malignancies
44. IgG1 plasmacytosis in interleukin 6 transgenic mice
45. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice
46. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene
47. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)
48. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells
49. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo
50. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
51. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas
52. Rapid induction of plasmacytomas in mice by pristane and a murine recombinant retrovirus containing an avian v-myc and a defective raf oncogene
53. Chromosomal translocations activating myc sequences and transduction of vabl are critical events in the rapid induction of plasmacytomas by pristane and Abelson virus
54. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors
55. Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice
56. A routine model of human myeloma bone disease
57. Multiple myeloma and related disorders. Lessons from an animal model
58. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma
59. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
60. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using 5T33 murine myeloma model
61. Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease
62. Long-term engraftment of fresh human myeloma cells in SCID
63. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease
64. The SCID mouse as a model for multiple myeloma
65. Development of an in vivo model of human multiple myeloma bone disease
66. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor
67. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma
68. A comparison of a CB17 SCID mouse model and the tetrazolium-dye assay using human haematological tumour cell lines
69. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo